Sep 15, 2026 · 22 min · 12 segments
Do you have a question? Send it now... **The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North…
Jeremy LevyHost
Andrew FrankelHost:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
For those who are interested in this, it's TA one one four eight, which relates to use of sodium zirconium cyclosilicate or Loquelma.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
And of course, now, um, in England, all of our integrated care boards have 90 days to implement these changes.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
The very simple key change that they've made, which on the face of it seems quite marginal, is that they've lowered the potassium threshold for starting Loquelma from six down to five point five.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
That might sound like a small adjustment, but Kidney Research UK together with AstraZeneca both estimate it roughly doubles the number of patients in England and Wales who now qualify for potassium binders because there's a large group of people sitting there persistently in that five point five to six range who previously were just monitored and given dietary advice.

It looks like it's trivial, but actually, that's a really, really big shift in, in the people who we could use potassium binders in.

A- and for us, it's really important in, in chronic kidney disease because it, it's that group where we're really trying to optimize and get people on maximum doses of renin-angiotensin blockade with ACE inhibitors and angiotensin blockers because the potassium is often what, what limits that.

So, so that's what we're gonna talk about because it, it's where the problem potentially lies, and in a way, we discussed that last w- time with finerenone, where, yeah, high potassiums might limit your use of a drug that's really protective for stopping or slowing down progression of chronic kidney disease.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
I should highlight, Jeremy, that the current change is specific to Loquelma, and there is, of course, another potassium binder, Patiromer.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
And Patiromer's, um, technology appraisal has not been reviewed, and its threshold is unchanged.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
But I anticipate, for common sense reasons, that there should be or there will be similar change for Patiromer, as it just doesn't make sense to have two different thresholds for each.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
For those who are interested in this, it's TA one one four eight, which relates to use of sodium zirconium cyclosilicate or Loquelma.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
And of course, now, um, in England, all of our integrated care boards have 90 days to implement these changes.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
The very simple key change that they've made, which on the face of it seems quite marginal, is that they've lowered the potassium threshold for starting Loquelma from six down to five point five.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
That might sound like a small adjustment, but Kidney Research UK together with AstraZeneca both estimate it roughly doubles the number of patients in England and Wales who now qualify for potassium binders because there's a large group of people sitting there persistently in that five point five to six range who previously were just monitored and given dietary advice.

It looks like it's trivial, but actually, that's a really, really big shift in, in the people who we could use potassium binders in.

A- and for us, it's really important in, in chronic kidney disease because it, it's that group where we're really trying to optimize and get people on maximum doses of renin-angiotensin blockade with ACE inhibitors and angiotensin blockers because the potassium is often what, what limits that.

So, so that's what we're gonna talk about because it, it's where the problem potentially lies, and in a way, we discussed that last w- time with finerenone, where, yeah, high potassiums might limit your use of a drug that's really protective for stopping or slowing down progression of chronic kidney disease.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
I should highlight, Jeremy, that the current change is specific to Loquelma, and there is, of course, another potassium binder, Patiromer.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
And Patiromer's, um, technology appraisal has not been reviewed, and its threshold is unchanged.
:max_bytes(150000):strip_icc():focal(216x0:218x2)/bridget-moynahan-wed-435-adb7dac57dd84a348760c98845a252df.jpg)
But I anticipate, for common sense reasons, that there should be or there will be similar change for Patiromer, as it just doesn't make sense to have two different thresholds for each.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.